Complife Italia srl
Milan, 20024, Italy
NCT Number: NCT06032598
The study is aimed to assess the efficacy of two dietary supplements composed of berry extracts in reducing skin aging signs and improving skin complexion.
Looking for future studies?
Notify Me35 year–65 year
Female
Interventional
Not applicable
Milan, 20024, Italy
A double blind, parallel groups, placebo-controlled study is carried out on 90 healthy female subjects aged between 35 and 65 (±2) years old with phototypes from I to III, uneven skin tone, visible Crow's feet wrinkles and mild-moderate skin slackness at cheek level.
The study foresees 84 days of products intake. Evaluations of the parameters under study are performed at baseline, after 28, 56 and 84 days of products consumption.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The study foresees the intake of 1 capsule per day during 84 days
The study foresees the intake of 1 capsule per day during 84 days
The study foresees the intake of 1 capsule per day during 84 days
Time frame: Baseline
Primos 3D
Time frame: 28 days
Primos 3D
Time frame: 56 days
Primos 3D
Time frame: 84 days
Primos 3D
Time frame: Baseline
Cutometer
Time frame: 28 days
Cutometer
Time frame: 56 days
Cutometer
Time frame: 84 days
Cutometer
Time frame: Baseline
CIELab color space
Time frame: 28 days
CIELab color space
Time frame: 56 days
CIELab color space
Time frame: 84 days
CIELab color space
Time frame: Baseline
Clinical evaluation (Skin Aging Atlas - Caucasian and Asian Type - Bazin Roland)
Time frame: 28 days
Clinical evaluation (Skin Aging Atlas - Caucasian and Asian Type - Bazin Roland)
Time frame: 56 days
Clinical evaluation (Skin Aging Atlas - Caucasian and Asian Type - Bazin Roland)
Time frame: 84 days
Clinical evaluation (Skin Aging Atlas - Caucasian and Asian Type - Bazin Roland)
Time frame: Baseline
Clinical scoring (internal validated scale from 1 to 5, where: 1 = not firm skin and 5 = very firm skin)
Time frame: 28 days
Clinical scoring (internal validated scale from 1 to 5, where: 1 = not firm skin and 5 = very firm skin)
Time frame: 56 days
Clinical scoring (internal validated scale from 1 to 5, where: 1 = not firm skin and 5 = very firm skin)
Time frame: 84 days
Clinical scoring (internal validated scale from 1 to 5, where: 1 = not firm skin and 5 = very firm skin)
Time frame: 28 days
Clinical scoring (internal validated scale from 1 to 4, where: 1 = no variation and 4 = evident variation)
Time frame: 56 days
Clinical scoring (internal validated scale from 1 to 4, where: 1 = no variation and 4 = evident variation)
Time frame: 84 days
Clinical scoring (internal validated scale from 1 to 4, where: 1 = no variation and 4 = evident variation)
Time frame: 84 days
Questionnaire (20 questions with 4 possible answers : completely agree / agree / disagree / completely disagree)
Time frame: Baseline
FRAP (Ferric Reducing Antioxidant Power) assay
Time frame: 84 days
FRAP (Ferric Reducing Antioxidant Power) assay
Seppic
Industry
Clinical-instrumental Evaluation of the Efficacy of Two Dietary Supplements Claiming Anti-aging Properties and Skin Complexion Improvement. A Double-blind, Randomized, Placebo-controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05447078
Healthy Volunteers, Infections
Jackson, Mississippi, United States
View Trial DetailsNCT07513532
Healthy Volunteers
Seattle, Washington, United States
View Trial DetailsNCT07090655
Healthy Volunteers
Brisbane, Australia
View Trial DetailsNCT01915212
Communicable Diseases, DNA Virus Infections
Bethesda, Maryland, United States
View Trial Details